• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鉴定五个免疫基因模型作为肝细胞癌的独立预后因素。

Identification of a five-immune gene model as an independent prognostic factor in hepatocellular carcinoma.

机构信息

Department of Orthopedic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.

Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.

出版信息

BMC Cancer. 2021 Mar 16;21(1):278. doi: 10.1186/s12885-021-08012-2.

DOI:10.1186/s12885-021-08012-2
PMID:33726698
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7962305/
Abstract

BACKGROUND

Hepatocellular carcinoma (HCC) is a common malignant tumor with a poor prognosis. We aimed to identify a new prognostic model of HCC based on differentially expressed (DE) immune genes.

METHODS

The DE immune genes were identified based on an analysis of 374 cases of HCC and 50 adjacent non-tumor specimens from the Cancer Genome Atlas (TCGA) database. Univariate Cox analysis, Lasso regression, and multivariate Cox analysis were used to construct the model based on the training group. Survival analysis and the receiver operating characteristic (ROC) curves were used to evaluate model performance. The testing group and the entire group were subsequently used for validation of the model.

RESULTS

A five-immune gene model consisted of HSPA4, ISG20L2, NDRG1, EGF, and IL17D was identified. Based on the model, the overall survival was significantly different between the high-risk and low-risk groups (P = 7.953e-06). The AUCs for the model at 1- and 3-year were 0.849 and 0.74, respectively. The reliability of the model was confirmed using the validation groups. The risk score was identified as an independent prognostic parameter and closely related to the content of immune cells from human HCC specimens.

CONCLUSION

We identified a five-immune gene model that can be used as an independent prognostic marker for HCC.

摘要

背景

肝细胞癌(HCC)是一种预后较差的常见恶性肿瘤。我们旨在基于差异表达(DE)免疫基因确定 HCC 的新预后模型。

方法

基于癌症基因组图谱(TCGA)数据库中 374 例 HCC 和 50 个相邻非肿瘤标本的分析,确定 DE 免疫基因。使用单因素 Cox 分析、Lasso 回归和多因素 Cox 分析基于训练组构建模型。生存分析和接收者操作特征(ROC)曲线用于评估模型性能。随后使用测试组和整个组验证模型。

结果

确定了由 HSPA4、ISG20L2、NDRG1、EGF 和 IL17D 组成的五个免疫基因模型。基于该模型,高风险和低风险组之间的总体生存率存在显著差异(P=7.953e-06)。模型在 1 年和 3 年的 AUC 分别为 0.849 和 0.74。使用验证组验证了模型的可靠性。风险评分被确定为独立的预后参数,与人类 HCC 标本中免疫细胞的含量密切相关。

结论

我们确定了一个可以用作 HCC 独立预后标志物的五个免疫基因模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/518f13186912/12885_2021_8012_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/cf9741caf58a/12885_2021_8012_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/efbd36967832/12885_2021_8012_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/6ba27eb49a93/12885_2021_8012_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/4d2041a0b10d/12885_2021_8012_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/8fb44e655825/12885_2021_8012_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/746c6b964bfa/12885_2021_8012_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/81b74a1f678d/12885_2021_8012_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/b88e8f5eb381/12885_2021_8012_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/3d26c4ec4a54/12885_2021_8012_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/364b6562a49c/12885_2021_8012_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/a69ef1b76732/12885_2021_8012_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/518f13186912/12885_2021_8012_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/cf9741caf58a/12885_2021_8012_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/efbd36967832/12885_2021_8012_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/6ba27eb49a93/12885_2021_8012_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/4d2041a0b10d/12885_2021_8012_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/8fb44e655825/12885_2021_8012_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/746c6b964bfa/12885_2021_8012_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/81b74a1f678d/12885_2021_8012_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/b88e8f5eb381/12885_2021_8012_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/3d26c4ec4a54/12885_2021_8012_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/364b6562a49c/12885_2021_8012_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/a69ef1b76732/12885_2021_8012_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3488/7962305/518f13186912/12885_2021_8012_Fig12_HTML.jpg

相似文献

1
Identification of a five-immune gene model as an independent prognostic factor in hepatocellular carcinoma.鉴定五个免疫基因模型作为肝细胞癌的独立预后因素。
BMC Cancer. 2021 Mar 16;21(1):278. doi: 10.1186/s12885-021-08012-2.
2
Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.基于肝癌微环境构建风险评分预后模型。
World J Gastroenterol. 2020 Jan 14;26(2):134-153. doi: 10.3748/wjg.v26.i2.134.
3
Identification and validation of redox-immune based prognostic signature for hepatocellular carcinoma.基于氧化还原免疫的肝细胞癌预后标志物的鉴定和验证。
Int J Med Sci. 2021 Mar 10;18(9):2030-2041. doi: 10.7150/ijms.56289. eCollection 2021.
4
Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.基于 TCGA 数据的肝癌肿瘤突变负荷和免疫浸润的预后分析。
Aging (Albany NY). 2021 Apr 4;13(8):11257-11280. doi: 10.18632/aging.202811.
5
Bioinformatics Analysis of Prognostic Tumor Microenvironment-Related Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.肝细胞癌肿瘤微环境中预后相关肿瘤微环境基因的生物信息学分析。
Med Sci Monit. 2020 Mar 31;26:e922159. doi: 10.12659/MSM.922159.
6
Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinoma.构建新型免疫相关 lncRNA 标志物,并预测其预测肝细胞癌患者免疫状态的潜力。
BMC Cancer. 2021 Dec 19;21(1):1347. doi: 10.1186/s12885-021-09059-x.
7
Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.基于上皮-间质转化相关基因 BIRC5 鉴定肝细胞癌的预后标志物。
BMC Cancer. 2021 Jun 10;21(1):687. doi: 10.1186/s12885-021-08390-7.
8
Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.肝细胞癌肿瘤微环境中的预后基因鉴定。
Front Immunol. 2021 Apr 7;12:653836. doi: 10.3389/fimmu.2021.653836. eCollection 2021.
9
Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach.基于统计与生物信息学综合分析方法构建并验证用于预测肝细胞癌患者总生存期的预后基因模型
Int J Mol Sci. 2021 Feb 5;22(4):1632. doi: 10.3390/ijms22041632.
10
Weighted correlation gene network analysis reveals a new stemness index-related survival model for prognostic prediction in hepatocellular carcinoma.加权相关基因网络分析揭示了一个新的与干细胞特性相关的生存模型,可用于预测肝细胞癌的预后。
Aging (Albany NY). 2020 Jul 9;12(13):13502-13517. doi: 10.18632/aging.103454.

引用本文的文献

1
as a driver in the proliferation and invasion of lung adenocarcinoma via regulation.作为通过调节在肺腺癌增殖和侵袭中的驱动因素。
Transl Cancer Res. 2025 Aug 31;14(8):5028-5044. doi: 10.21037/tcr-2025-1546. Epub 2025 Aug 27.
2
TTC36 as a prognostic biomarker in nonmetastatic hepatocellular carcinoma: A TCGA-based cohort study.TTC36作为非转移性肝细胞癌的预后生物标志物:一项基于TCGA的队列研究。
Medicine (Baltimore). 2025 Jul 11;104(28):e43135. doi: 10.1097/MD.0000000000043135.
3
Molecular mechanism of human ISG20L2 for the ITS1 cleavage in the processing of 18S precursor ribosomal RNA.

本文引用的文献

1
BRCA1-Associated Protein Is a Potential Prognostic Biomarker and Is Correlated With Immune Infiltration in Liver Hepatocellular Carcinoma: A Pan-Cancer Analysis.BRCA1相关蛋白是一种潜在的预后生物标志物,与肝细胞癌的免疫浸润相关:一项泛癌分析。
Front Mol Biosci. 2020 Nov 2;7:573619. doi: 10.3389/fmolb.2020.573619. eCollection 2020.
2
Development of a Nomogram With Alternative Splicing Signatures for Predicting the Prognosis of Glioblastoma: A Study Based on Large-Scale Sequencing Data.基于大规模测序数据构建用于预测胶质母细胞瘤预后的可变剪接特征列线图的研究
Front Oncol. 2020 Jul 22;10:1257. doi: 10.3389/fonc.2020.01257. eCollection 2020.
3
人源 ISG20L2 在 18S 前体核糖体 RNA 加工中 ITS1 切割的分子机制。
Nucleic Acids Res. 2024 Feb 28;52(4):1878-1895. doi: 10.1093/nar/gkad1210.
4
ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.ISG20L2 通过削弱硼替佐米与 PSMB5 的结合来抑制硼替佐米的抗骨髓瘤活性。
JCI Insight. 2022 Oct 10;7(19):e157081. doi: 10.1172/jci.insight.157081.
5
Exploring potential targets of Actinidia chinensis Planch root against hepatocellular carcinoma based on network pharmacology and molecular docking and development and verification of immune-associated prognosis features for hepatocellular carcinoma.基于网络药理学和分子对接探索中华猕猴桃根抗肝细胞癌的潜在靶点及肝细胞癌免疫相关预后特征的建立与验证
J Gastrointest Oncol. 2022 Jun;13(3):1289-1307. doi: 10.21037/jgo-22-398.
6
Significant correlation between HSPA4 and prognosis and immune regulation in hepatocellular carcinoma.热休克蛋白家族A成员4(HSPA4)与肝细胞癌的预后及免疫调节之间存在显著相关性。
PeerJ. 2021 Oct 26;9:e12315. doi: 10.7717/peerj.12315. eCollection 2021.
Comprehensive Analysis of Prognostic Alternative Splicing Signatures in Endometrial Cancer.
子宫内膜癌预后性可变剪接特征的综合分析
Front Genet. 2020 May 29;11:456. doi: 10.3389/fgene.2020.00456. eCollection 2020.
4
Identification of a Subtype of Hepatocellular Carcinoma with Poor Prognosis Based on Expression of Genes within the Glucose Metabolic Pathway.基于葡萄糖代谢途径中基因表达鉴定预后不良的肝细胞癌亚型
Cancers (Basel). 2019 Dec 14;11(12):2023. doi: 10.3390/cancers11122023.
5
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers.肝细胞癌免疫治疗的原理及其潜在生物标志物
Cancers (Basel). 2019 Dec 3;11(12):1926. doi: 10.3390/cancers11121926.
6
A Bioinformatic Approach for the Identification of Molecular Determinants of Resistance/Sensitivity to Cancer Thermotherapy.一种用于鉴定癌症热疗耐药/敏感分子标志物的生物信息学方法。
Oxid Med Cell Longev. 2019 Nov 11;2019:4606219. doi: 10.1155/2019/4606219. eCollection 2019.
7
Immunotherapy for hepatocellular carcinoma.肝细胞癌的免疫治疗。
Cancer Lett. 2020 Feb 1;470:8-17. doi: 10.1016/j.canlet.2019.12.002. Epub 2019 Dec 4.
8
PD1 CD8 T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma.PD1 CD8 T 细胞与肝癌衰竭特征和不良临床结局相关。
J Immunother Cancer. 2019 Nov 29;7(1):331. doi: 10.1186/s40425-019-0814-7.
9
Multi-omics Analysis of Microenvironment Characteristics and Immune Escape Mechanisms of Hepatocellular Carcinoma.肝细胞癌微环境特征及免疫逃逸机制的多组学分析
Front Oncol. 2019 Oct 15;9:1019. doi: 10.3389/fonc.2019.01019. eCollection 2019.
10
An eight-mRNA signature predicts the prognosis of patients with bladder urothelial carcinoma.一种八信使核糖核酸特征可预测膀胱尿路上皮癌患者的预后。
PeerJ. 2019 Oct 22;7:e7836. doi: 10.7717/peerj.7836. eCollection 2019.